BLA 021663 · Ferring
Menopur
Menotropins (Fsh, Lh) · Subcutaneous
Last checked: Nov 19, 2026Latest source record: Jul 8, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2004
Oct 29, 2004
Approved uses
2
Original approval plus efficacy supplements
Registered trials
n/a
n/a Phase 3, n/a recruiting
FAERS reports
2,221
1,027 serious, 32 with death reported
AI brief across all sources
Written by Claude (Anthropic's AI) from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 31, 2018.
MENOPUR ® (menotropins for injection) is a gonadotropin indicated for: Development of multiple follicles and pregnancy in ovulatory women as part of an Assisted Reproductive Technology (ART) cycle ( 1 ) Development of Multiple Follicles and Pregnancy in Ovulatory Women as Part of an Assisted Reproductive Technology (ART) Cycle Prior to initiation of treatment with MENOPUR ® (menotropins for injection): Perform a complete gynecologic and endocrinologic evaluation, and diagnose the cause of infertility Exclude the possibility of pregnancy Evaluate the fertility status of the male partner Exclude a diagnosis of primary ovarian failure
Mechanism: MENOPUR, administered for 7 to 20 days, produces ovarian follicular growth and maturation in women who do not have primary ovarian failure. Treatment with MENOPUR in most instances results only in follicular growth and maturation. When sufficient follicular maturation has occurred, hCG must be given to induce ovulation.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 19, 2014 Supplement 14 · Efficacy LabelLetter
- Oct 29, 2004 Original approval · Type 3 - New Dosage Form LetterLabelReview
1 products under this application
- MENOPUR · MENOTROPINS (FSH 75 IU/VIAL; LH) 75 IU/VIAL · INJECTABLE, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Menotropins (Fsh" as an intervention, any sponsor and status, largest first.
No registered drug trials name this ingredient.
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- ovarian hyperstimulation syndrome434
- abdominal distension198
- drug ineffective178
- injection site pain151
- headache141
- nausea133
- abdominal pain115
- ascites95
- dyspnoea84
- inappropriate schedule of drug administration81
- fatigue73
- abortion spontaneous69
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 11 |
| 2005 | 19 |
| 2006 | 21 |
| 2007 | 45 |
| 2008 | 37 |
| 2009 | 21 |
| 2010 | 30 |
| 2011 | 36 |
| 2012 | 38 |
| 2013 | 63 |
| 2014 | 82 |
| 2015 | 80 |
| 2016 | 88 |
| 2017 | 149 |
| 2018 | 114 |
| 2019 | 263 |
| 2020 | 148 |
| 2021 | 197 |
| 2022 | 166 |
| 2023 | 169 |
| 2024 | 135 |
| 2025 | 127 |
| 2026 | 182 |
Recalls
1 FDA enforcement reports for this application.
Mar 2, 2021 · Class III · Terminated
Failed pH specifications: Out of Specification pH results for 0.9% Sodium Chloride, USP
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Randomized, assessor-blinded trial comparing highly purified human menotropin and recombinant follicle-stimulating hormone in high responders undergoing intracytoplasmic sperm injection.
Witz CA, Daftary GS, Doody KJ, et al. · Fertil Steril 2020 · Comparative Study, Equivalence Trial
- Subcutaneously administered Menopur, a new highly purified human menopausal gonadotropin, causes significantly fewer injection site reactions than Repronex in subjects undergoing in vitro fertilization.
Keye WR, Webster B, Dickey R, et al. · Reprod Biol Endocrinol 2005 · Multicenter Study, Randomized Controlled Trial
- First pre-filled pen device with highly purified human menopausal gonadotropin (HP-hMG, Menopur) in liquid is shown to be bioequivalent to powder for reconstitution.
Jonker DM, Koch M, Larsson P, et al. · Int J Clin Pharmacol Ther 2021 · Randomized Controlled Trial
- Human menopausal gonadotrophin in a pre-filled injection pen is non-inferior to the US-approved powder formulation.
Witz C, Foster ED, Grover SA, et al. · Reprod Biomed Online 2026 · Randomized Controlled Trial, Multicenter Study
- Clinical efficacy and safety of two highly purified human menopausal gonadotropins in women undergoing in vitro fertilization.
Rao KA, Khanna G, Bavishi H, et al. · Reprod Fertil 2025 · Randomized Controlled Trial, Multicenter Study
- Clinical efficacy of highly purified hMG versus recombinant FSH in IVF/ICSI cycles: a meta-analysis.
Jee BC, Suh CS, Kim YB, et al. · Gynecol Obstet Invest 2010 · Comparative Study, Meta-Analysis
Sponsor: Ferring
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.